Side-by-side · Research reference
LL-37vsProstamax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED15/35 cited
BAnimal-MechanisticHUMAN-REVIEWED11/38 cited
LL-37
Cathelicidin · Human AMP
Broad-spectrumAntimicrobial activity
Endogenous · Secreted at inflammation sites
Prostamax
Khavinson Bioregulator · Tissue-Specific Peptide
4 AAPeptide length
SQ · Protocol per Khavinson tradition
01Mechanism of Action
Parameter
LL-37
Prostamax
Primary target
Chromatin in prostatic cells — pericentromeric heterochromatin regions
Pathway
hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption
Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012
Downstream effect
Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026Zhang 2026
Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012Zakutskiĭ 2006
Feedback intact?
—
—
Origin
Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)
Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017
Antibody development
—
—
02Dosage Protocols
Parameter
LL-37
Prostamax
Endogenous expression
Constitutive in neutrophils, epithelial tissues
Upregulated during infection and inflammation.Pinheiro 2026
—
Exogenous (experimental)
Dose varies by study; antimalarial ~10–50 μM in vitro
No FDA-approved exogenous formulation.
—
Plasma levels (malaria)
Elevated in infected patients and miceHe 2026
Exogenous administration reduced parasitemia in murine models.He 2026
—
Evidence basis
In vitro, animal models, human observational
Animal / organotypic cultureZakutskiĭ 2006Dzhokhadze 2012
No randomized controlled trials in humans.
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic culture model; demonstrated tissue-specific stimulation.
Human clinical dose
—
Not established
No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).
Age groups studied
—
Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006Dzhokhadze 2012
Duration
—
Not specified
Khavinson protocols typically 10–20 days per cycle; no long-term safety data.
04Side Effects & Safety
Parameter
LL-37
Prostamax
Cytotoxicity (high dose)
Membrane disruption in host cells at supraphysiological concentrations
—
Pro-inflammatory signaling
Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026
—
Theoretical cancer risk
Immunomodulatory roles in tumor microenvironment under investigation
—
Published adverse events
—
None reported in available literature
Genotoxicity signals
—
Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications
Metal ion interactions
—
Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance
Human safety data
—
Absent — no published Phase 1/2/3 trials
Absolute Contraindications
LL-37
—Prostamax
- ·Active prostate malignancy — epigenetic modulation effects unknown in cancer
Relative Contraindications
LL-37
- ·Active autoimmune disease (theoretical immune dysregulation)
Prostamax
- ·History of prostate cancer — theoretical concern re: transcriptional activation
- ·Undiagnosed prostatic nodules or elevated PSA
05Administration Protocol
Parameter
LL-37
Prostamax
1. Natural secretion
LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.
Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.
2. Experimental formulations
Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.
If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).
3. Stability considerations
LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026
Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.
4. Monitoring
—
No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).
5. Note
—
All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.